Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00945191 |
Recruitment Status :
Completed
First Posted : July 24, 2009
Last Update Posted : February 5, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer | Drug: CS-1008 Drug: paclitaxel Drug: carboplatin | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 2 Study of CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or Metastatic Ovarian Cancer |
Study Start Date : | September 2009 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: CS-1008 with paclitaxel and carboplatin
CS-1008 will be administered with paclitaxel and carboplatin.
|
Drug: CS-1008
CS-1008 IV infusion up to 10 mg/kg once every 3 weeks (1 cycle) for 6 cycles Drug: paclitaxel paclitaxel 175 mg/m2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
Other Name: Taxol Drug: carboplatin carboplatin (target area under the concentration versus time curve of 6.0 using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles |
- percentage of subjects with complete response after 6 cycles of treatment based on RECIST criteria [ Time Frame: 18 weeks = 6 cycles ]
- objective response rate (all subjects) [ Time Frame: 18 weeks = 6 cycles ]
- duration of complete response [ Time Frame: 18 weeks = 6 cycles ]
- overall survival (subjects that achieve a complete response) [ Time Frame: 18 weeks = 6 cycles ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed, epithelial carcinoma of the ovary or primary peritoneal carcinoma (FIGO Stage IIIC or IV). (Subjects with the following histologic epithelial cell types are eligible for the study: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified.)
- Enrollment within 6 weeks after surgical resection (debulking).
- Residual tumor masses > 1 cm and objectively measurable/evaluable disease as defined by RECIST criteria.
- No prior therapy for ovarian cancer (ie, chemotherapy or radiotherapy [RT] to the abdomen or pelvis) other than surgical debulking of disease.
- At least 18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
-
Adequate organ and bone marrow function as evidenced by:
- Absolute neutrophil count ≥ 1,500/µL (equivalent to NCI CTCAE, Version 3.0 grade 1)
- Platelet count ≥ 100,000/µL (CTCAE grade 0 to 1)
- Hemoglobin ≥ 9 g/dL
- Serum creatinine ≤ 1.5 x institutional ULN (CTCAE grade 1)
- Bilirubin ≤ 1.5 x ULN (CTCAE grade 1)
- AST and alkaline phosphatase ≤ 2.5 x ULN (CTCAE grade 1)
- Adequate neurologic function (ie, sensory and motor neuropathy ≤ CTCAE grade 1).
- Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for 3 months thereafter.
- All subjects of childbearing potential must have a negative pregnancy test (serum or urine) result ≤ 72 hours before initiating study treatment.
- Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IRB-approved ICF before performance of any study-specific procedures or tests.
Exclusion Criteria:
- Prior invasive malignant disease within 5 years except for squamous cell or basal cell carcinoma.
- Current diagnosis of borderline epithelial ovarian tumor (formerly "tumors of low malignant potential") or recurrent ovarian epithelial cancer.
- Positive human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg) because of the potential for additional toxicity from the treatment regimen.
- Anticipation of need for a major surgical procedure or RT during the study.
- History of any of the following conditions within 6 months before study enrollment: myocardial infarction; severe/unstable angina pectoris; coronary/peripheral artery bypass graft; New York Heart Association (NYHA) class III or IV congestive heart failure; cerebrovascular accident or transient ischemic attack, pulmonary embolism, or other clinically significant thromboembolic event; clinically significant pulmonary disease (eg, severe chronic obstructive pulmonary disease or asthma).
- Clinically active brain metastasis (ie, untreated, still requiring therapy with steroids or RT, or with progression within 4 weeks after completion of RT); an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.
- Pregnant or lactating.
- Prior treatment with CS-1008, other agonistic DR5 antibodies, or TRAIL.
- Known history of hypersensitivity reactions to any of the components of CS-1008, paclitaxel (or docetaxel), or carboplatin formulations.
- Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00945191
United States, Alabama | |
Univ. Alabama | |
Birmingham, Alabama, United States, 35233 | |
United States, Missouri | |
Barnes Jewish Hospital | |
St. Louis, Missouri, United States, 63110 | |
United States, Oklahoma | |
University of Oklahoma | |
Oklahoma City, Oklahoma, United States, 73104 |
Responsible Party: | Daiichi Sankyo, Inc. |
ClinicalTrials.gov Identifier: | NCT00945191 History of Changes |
Other Study ID Numbers: |
CS1008-A-U205 |
First Posted: | July 24, 2009 Key Record Dates |
Last Update Posted: | February 5, 2013 |
Last Verified: | February 2013 |
Keywords provided by Daiichi Sankyo, Inc.:
ovarian cancer metastatic locally |
advanced chemotherapy neoplasm |
Additional relevant MeSH terms:
Ovarian Neoplasms Neoplasms, Glandular and Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases |
Gonadal Disorders Neoplasms by Histologic Type Paclitaxel Albumin-Bound Paclitaxel Carboplatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |